title: Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
abstract: We review and analyze approaches over a 65 year period that have proven successful for onchocerciasis control in several different epidemiological settings. These include vector control with the goal of transmission interruption versus the use of mass drug administration using ivermectin (Mectizan(®)) monotherapy. Ivermectin has proven exceedingly effective because it is highly efficacious against Onchocerca volvulus microfilariae, the etiological agent of onchocercal skin and ocular disease and the infective stage for the vector. For these reasons, the drug was donated by the Merck Company for regional control programs in Africa and the Americas. Recurrent treatment with ivermectin at semi-annual intervals also impacts adult worms and result in loss of fecundity and increased mortality. Using a strategy of 6-monthly treatments with high coverage rates, the Onchocerciasis Elimination Program for the Americas has interrupted transmission in seven of the thirteen foci in the Americas and is on track to eliminate onchocerciasis in the region by 2015. Treatments given annually or semi-annually for 15-17 years in three hyperendemic onchocerciasis foci in Mali and Senegal also have resulted in a few infections in the human population with transmission levels below thresholds postulated for elimination. Follow-up evaluations did not detect any recrudescence of infection or transmission, suggesting that onchocerciasis elimination could be feasible with Mectizan(®) treatment in some endemic foci in Africa.
authors.affiliation: Department of Entomology and Plant Pathology, Auburn University, Auburn, AL 36849, USA. cuppedd@auburn.edu
authors.forename: E W
authors.initials: EW
authors.lastname: Cupp
authors.forename: M
authors.initials: M
authors.lastname: Sauerbrey
authors.forename: F
authors.initials: F
authors.lastname: Richards
mesh_terms: D000349:Africa / Q000453:epidemiology; D000569:Americas / Q000453:epidemiology; D000818:Animals; D005369:Filaricides / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008302:Mali / Q000453:epidemiology; D008842:Microfilariae / Q000187:drug effects*; D017181:Onchocerca volvulus / Q000187:drug effects* / Q000254:growth & development; D009855:Onchocerciasis / Q000188:drug therapy / Q000453:epidemiology* / Q000469:parasitology / Q000635:transmission; D012675:Senegal / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D005369:Filaricides; D007559:Ivermectin